Related Experiment Videos
Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension
D Abrams1, I Schulze-Neick, A G Magee
1Department of Paediatric Cardiology, Royal Brompton & Harefield NHS Trust, Sydney Street, London SW3 6NP, UK.
Insights
This study explores sildenafil as a novel treatment for childhood primary pulmonary hypertension, a severe condition. Early results show improved exercise capacity and quality of life in a young patient.
Area of Science:
- Pediatric Cardiology
- Pulmonary Hypertension Research
- Pharmacological Interventions
Background:
- Primary pulmonary hypertension in children is a rare, severe condition with a poor prognosis and limited life expectancy.
- Current treatments include vasodilators like calcium antagonists and long-term prostacyclin, with heart-lung transplantation as a last resort for refractory cases.
- The case focuses on a 4-year-old Bangladeshi girl presenting with severe symptoms of pulmonary hypertension.
Observation:
- The patient initially received prostacyclin treatment, which was gradually reduced.
- Oral sildenafil (Viagra) was initiated as maintenance therapy.
- Clinical assessment at 3-month follow-up revealed significant improvements.
Findings:
- The young patient demonstrated greatly improved exercise capacity.
- She experienced a good quality of life with no discernible side effects from sildenafil treatment.
- These initial results suggest a positive response to oral sildenafil.
Implications:
- Sildenafil may represent a viable and effective adjunct therapy for pediatric primary pulmonary hypertension.
- Further research is warranted to confirm its efficacy and safety in a broader patient group.
- This finding could offer new therapeutic avenues for children suffering from this debilitating disease.
Abstract:
Primary pulmonary hypertension is a rare disease of childhood, which carries a poor prognosis. Patients often present with severe exercise limitation, and untreated life expectancy is less than 1 year. Pharmacological intervention is directed towards reduction of the raised pulmonary artery pressure with vasodilator treatment, initially with calcium antagonists, although more recently long term prostacyclin treatment has shown benefit in some patients. Heart-lung transplantation remains an option for children with severe disease refractory to therapeutic treatment. A 4 year old Bangladeshi girl with dyspnoea, cyanosis, and signs of a low cardiac output, is described. Initial treatment with prostacyclin was gradually reduced, and maintenance treatment with oral sildenafil (Viagra; Pfizer) instituted. At follow up 3 months later, her exercise capacity was greatly improved and she continues to enjoy a good quality of life without obvious side effects. In view of the encouraging initial results, this may become an acceptable adjunct in treating this patient group.